

Barbara Mc McGowan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8146141/publications.pdf>

Version: 2024-02-01

22
papers

2,872
citations

567144

15
h-index

713332

21
g-index

22
all docs

22
docs citations

22
times ranked

3560
citing authors

#	ARTICLE	IF	CITATIONS
1	GLP-1 analogues in clinical management of obesity. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, , 100360.	0.6	3
2	The Bariatric-Metabolic Physician's Role in Managing Clinically Severe Obesity. <i>Current Obesity Reports</i> , 2021, 10, 263-273.	3.5	8
3	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. <i>BMJ Open</i> , 2020, 10, e034137.	0.8	5
4	Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 549-559.	5.5	100
5	Suboptimal rise in awakening-induced cortisol is an accurate marker of cortisol insufficiency in patients with normal renal function (eGFR >60 mL/min). <i>Annals of Clinical Biochemistry</i> , 2018, 55, 496-499.	0.8	0
6	Clinical Practice Recommendations for the Management of Obesity in the United Arab Emirates. <i>Obesity Facts</i> , 2018, 11, 413-428.	1.6	13
7	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. <i>Lancet</i> , 2018, 392, 637-649.	6.3	446
8	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet</i> , 2017, 389, 1399-1409.	6.3	502
9	The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 92-107.	1.1	35
10	Relaxin-3 stimulates the neuro-endocrine stress axis via corticotrophin-releasing hormone. <i>Journal of Endocrinology</i> , 2014, 221, 337-346.	1.2	35
11	The bariatric physician. <i>Clinical Medicine</i> , 2014, 14, 30-33.	0.8	8
12	The Prevalence and Natural History of Pituitary Hemorrhage in Prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2362-2367.	1.8	68
13	Pituitary involvement in Wegener's granulomatosis: unusual biochemical findings and severe malnutrition. <i>BMJ Case Reports</i> , 2011, 2011, bcr0220113850-bcr0220113850.	0.2	14
14	Co-morbidities, management and clinical outcome of auto-immune Addison's disease. <i>Endocrine</i> , 2010, 38, 113-117.	1.1	43
15	No evidence of an additive inhibitory feeding effect following PP and PYY3-36 administration. <i>International Journal of Obesity</i> , 2008, 32, 1438-1440.	1.6	29
16	The effect of a 12-week low glycaemic index diet on heart disease risk factors and 24h glycaemic response in healthy middle-aged volunteers at risk of heart disease: a pilot study. <i>European Journal of Clinical Nutrition</i> , 2008, 62, 145-149.	1.3	30
17	Low-dose pancreatic polypeptide inhibits food intake in man. <i>British Journal of Nutrition</i> , 2007, 97, 426-429.	1.2	65
18	Effects of acute and chronic relaxin-3 on food intake and energy expenditure in rats. <i>Regulatory Peptides</i> , 2006, 136, 72-77.	1.9	110

#	ARTICLE	IF	CITATIONS
19	Kisspeptin-54 Stimulates the Hypothalamic-Pituitary Gonadal Axis in Human Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6609-6615.	1.8	574
20	Appetite control. <i>Journal of Endocrinology</i> , 2005, 184, 291-318.	1.2	419
21	Hormonal Regulation of Food Intake. <i>Physiological Reviews</i> , 2005, 85, 1131-1158.	13.1	301
22	Peptide YY and appetite control. <i>Current Opinion in Pharmacology</i> , 2004, 4, 583-588.	1.7	64